Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations
Cancer Management and Research · 2025-02 · Volume 17 · 211-217
DOI: 10.2147/cmar.s379963 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Management and Research, 2025-02. Verfasst von Matthew Stewart und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Primary Care Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Primary Care Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Zitieren
APA
Stewart, M., & Geiger, J. L. (2025). Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations. Cancer Management and Research, Volume 17, 211-217. https://doi.org/10.2147/cmar.s379963
Vancouver
Stewart M, Geiger JL. Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations. Cancer Management and Research. 2025;Volume 17:211-217. doi:10.2147/cmar.s379963
BibTeX
@article{Stewart2025,
author = {Stewart, Matthew and Geiger, Jessica L},
title = {Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations},
journal = {Cancer Management and Research},
year = {2025},
volume = {Volume 17},
pages = {211--217},
doi = {10.2147/cmar.s379963}
}
EUVIMED